Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Next-generation sequencing is useful for quantitative analysis of the transcriptome of HMME-RGD@C3F8 NBs under low-frequency ultrasound irradiation combined with Elesclomol-Cu treated and untreated HCC cells

ABSTRACT: Hepatocellular carcinoma has a hidden onset and is often found at an advanced stage clinically. Moreover, because it is insensitive to radiotherapy and chemotherapy, its treatment is often difficult. In this study, we constructed nanobubbles loaded with sonosensitizer HMME and tumor-targeting peptide RGD (HMME-RGD@C3F8 NBs) combined with cuproptosis inducer Elesclomol-Cu to achieve sonodynamic/cuproptosis combined therapy for hepatocellular carcinoma (HCC). Furthermore, to explore the mechanism of the enhanced anti-tumor efficacy of synergistic sonodynamic/cuproptosis therapy, RNA sequencing was performed.

ORGANISM(S): Homo sapiens

PROVIDER: GSE274917 | GEO | 2025/08/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Next-generation sequencing is useful for quantitative analysis of the transcriptome of HMME-RGD@C3F8 NBs under low-frequency ultrasound irradiation combined with Elesclomol-Cu treated and untreated HCC cells

Project description:Next-generation sequencing is useful for quantitative analysis of the transcriptome of HMME-RGD@C3F8 NBs under low-frequency ultrasound irradiation combined with Elesclomol-Cu treated and untreated HCC cells

| PRJNA1148468 | ENA

AKT1 confers tumor resistance to cuproptosis by phosphorylating FDX1

Project description:Cuproptosis, a recently defined copper-dependent cell death, remains largely unexplored in tumor therapies, particularly in breast cancer. Our study demonstrates that triple-negative breast cancer (TNBC) bears a relative elevated copper levels and exhibit resistance to cuproptosis. Mechanistically, cooper activates AKT1 signaling pathway, which inhibits cuproptosis by directly phosphorylating ferredoxin-1 (FDX1), a key regulator involved in cuproptosis. AKT1-mediated FDX1 phosphorylation abrogates FDX1-induced cuproptosis and aerobic respiration, accompanied by promoting glycolysis. Consequently, combination of AKT1 inhibitors MK2206 and the copper ionophore elesclomol (ES) synergistically inhibits TNBC tumorigenesis both in vitro and in vivo. In summary, our findings uncover a critical mechanism underlying TNBC resistance to cuproptosis and propose a potential therapeutic approach for TNBC.

2025-05-07 | PXD058176 | Pride

Isocitrate Dehydrogenase 1 Primes Group-3 Medulloblastomas For Cuproptosis

Project description:MYC-driven Group-3 medulloblastomas (MB) are malignant pediatric brain cancers without cures. To define actionable metabolic dependencies, we identified upregulationof dihydrolipoyl transacetylase (DLAT), the E2-subunit of pyruvate dehydrogenasecomplex (PDC) in a subset of Group-3 MB with poor prognosis. DLAT was induced by c-MYC and targeting DLAT lowered TCA-cycle metabolism and glutathione synthesis in Group-3 MB cells. We also noted upregulation of isocitrate dehydrogenase 1 (IDH1) in Group-3 MB. Remarkably, genetic and pharmacologic suppression of IDH1 epigenetically reduced c-MYC and downstream DLAT levels. DLAT is a central regulator of cuproptosis, a copper-dependent cell death mechanism induced by the copper ionophore elesclomol. DLAT expression in Group-3 MB cells correlated with increased sensitivity to cuproptosis. Elesclomol was CNS-penetrant and suppressed tumor growth in vivo in Group-3 MB animal models. Our data uncover an IDH1/c-MYC dependent vulnerability that regulates DLAT levels and can be targeted to kill Group-3MB by cuproptosis.

2025-04-10 | GSE278880 | GEO

Hs 294T Cells Treated with Elesclomol Alone or in Combination with NAC Compared to DMSO Treated

2008-05-29 | GSE11551 | GEO

Hs 294T Cells Treated with Elesclomol Alone or in Combination with Paclitaxel Compared to DMSO Treated

2008-05-29 | GSE11550 | GEO

Dysregulated Wnt signaling confers resistance to cuproptosis in cancer stem cells

Project description:Cuproptosis is characterized by the aggregation of lipoylated components of the tricarboxylic acid cycle and subsequent loss of iron-sulfur cluster proteins as a unique copper-dependent form of regulated cell death. Dysregulation of copper homeostasis and resulting cuproptosis induction is an emerging area of interest for cancer therapy. However, mechanisms of cancer cell evasion of cuproptosis are not well understood. Here, we found that the cuproptosis process is accompanied by activation of the Wnt/β-catenin pathway. Mechanistically, copper binds to PDK1 and promotes its interaction with AKT, resulting in activation of the Wnt/β-catenin pathway and cancer stem cell (CSC) properties. Notably, aberrant activation of Wnt/β-catenin signaling conferred resistance of CSCs to cuproptosis. Further studies showed that the β-catenin/TCF4 transcriptional complex directly binds to the promoter region of ATP7B, a protein responsible for the efflux of copper ions from the cell, inducing its expression and reducing intracellular copper accumulation, thereby inhibiting cuproptosis. Knockdown of TCF4 or pharmacological blockade of the Wnt/β-catenin pathway increased the sensitivity of CSCs to elesclomol-Cu-induced cuproptosis. These findings reveal a link between copper homeostasis regulated by the Wnt/β-catenin pathway and cuproptosis sensitivity, and may provide a precision medicine strategy for cancer treatment by selectively inducing cuproptosis

2023-11-21 | GSE248084 | GEO

Dysregulated Wnt signaling confers resistance to cuproptosis in cancer cells

2023-11-21 | GSE248083 | GEO

Transcription profiling of human Hs 294T cells treated with elesclomol alone or in combination with paclitaxel compared to DMSO treated

Project description:We used microarrays to detail gene expression changes in Hs 294T human melanoma cells after treatment with elesclomol alone, or in combination with paclitaxel, to aide in identifing the mechnism of action of elesclomol. Experiment Overall Design: Hs 294T human melanoma cells were grown in vitro. They were seeded at a low density and were left untreated, treated with the vehicle, treated with elesclomol, treated with paclitaxel, or treated in combination with both elesclomol and paclitaxel. They were incubated for 6 hours before harvesting.

2008-06-19 | E-GEOD-11550 | biostudies-arrayexpress

Transcription profiling of human 294T Cells treated with elesclomol alone or in combination with NAC compared to DMSO treated

Project description:We used microarrays to detail gene expression changes in Hs 294T human melanoma cells after treatment with elesclomol alone, or in combination with NAC, to aide in identifing the mechnism of action of elesclomol. Experiment Overall Design: Hs 294T human melanoma cells were grown in vitro. They were seeded at a low density and were left untreated, treated with the vehicle, treated with elesclomol, treated with NAC, or treated in combination with both elesclomol and NAC. The cells treated with NAC were given the NAC 30 minutes prior to additional treatments. They were incubated for 6 hours before harvesting.

2008-06-18 | E-GEOD-11551 | biostudies-arrayexpress

Transcription profiling of human 294T cells treated with elesclomol in combination with paclitaxel or NAC

Project description:This SuperSeries is composed of the following subset Series:; GSE11550: Hs 294T Cells Treated with Elesclomol Alone or in Combination with Paclitaxel Compared to DMSO Treated; GSE11551: Hs 294T Cells Treated with Elesclomol Alone or in Combination with NAC Compared to DMSO Treated Experiment Overall Design: Refer to individual Series

2008-06-19 | E-GEOD-11552 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data